Skip to main navigation

Main Menu

Header Nav

Our science
our pipeline
disease focus: HAE
HAE community
clinical trials
About us
Investors

Investor Menu

IR Nav

Overview
News & Events
Financials
- SEC Filings
Stock
- Stock Performance
- Analyst Coverage
Corporate Governance
Resources

Events & Presentations

Breadcrumb

Home / Investor Relations / NEWS & EVENTS / NEWS & EVENTS >> Events & Presentations

Past Events

2023 HAEi Regional Conference APAC

Mar 18, 2023 at 11:35 AM +07

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 920.2 KB

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Oppenheimer 33rd Annual Healthcare Conference

Mar 13, 2023 at 8:00 AM EDT

Click for Webcast

BioCapital Europe 2023

Mar 09, 2023

AAAAI Annual Meeting 2023

Feb 26, 2023 at 9:45 AM CST

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 1.1 MB

Dr. Marcus Maurer Audio Session (MP4) 6.3 MB

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

SVB Securities Global Biopharma Conference

Feb 15, 2023 at 8:40 AM EST

Click for Webcast

RAPIDe-1 Phase 2 Top-line Data

Dec 08, 2022 at 8:00 AM EST

Click for Webcast

Supporting Materials

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks 193.1 KB

RAPIDe-1 Phase 2 Top-line Data Presentation 2.2 MB

ACAAI Annual Scientific Meeting 2022

Nov 10 - Nov 14, 2022

Supporting Materials

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022

Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks 818.4 KB

Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist 937.4 KB

2022 HAEi Global Leadership Workshop

Oct 07, 2022 at 2:30 PM CEST

Supporting Materials

Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema 920.1 KB

2022 Bradykinin Symposium

Sep 16, 2022 at 10:45 AM CEST

Supporting Materials

Development of PHA121 for On-Demand and Prophylactic Treatment of HAE 926.6 KB

Morgan Stanley 20th Annual Global Healthcare Conference

Sep 12, 2022 at 4:15 PM EDT

Click for Webcast

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Presentations

Corporate Presentation

Toolkit

Print Page

Email Alerts

IR Contacts

Footer Links

Privacy Cookie notice Terms of Use

Social Links

Pharvaris 2020 - © All rights reserved